Botulinum toxin in urology: Evaluation using an evidence-based medicine approach

Nature Clinical Practice Urology

Volumn 1, Issue 1, 2004, Pages 31-37

  Smith, Christopher P ^a   Somogyi, George T ^a   Boone, Timothy B ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Bladder; Botulinum toxin; Evidence based medicine; Prostate; Urethra

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; PLACEBO; RESINIFERATOXIN;

BLADDER DYSFUNCTION; BLADDER SPHINCTER; CLINICAL PRACTICE; CLINICAL STUDY; CLINICAL TRIAL; DETRUSOR DYSSYNERGIA; DETRUSOR MUSCLE; DRUG MECHANISM; EVIDENCE BASED MEDICINE; HUMAN; HYPERREFLEXIA; IDIOPATHIC DISEASE; INTERSTITIAL CYSTITIS; MEDICAL DOCUMENTATION; NEUROGENIC BLADDER; OVERACTIVE BLADDER; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SPASTICITY; URETHRA DISEASE; URINARY TRACT DISEASE; UROLOGY;

BOTULINUM TOXINS; EVIDENCE-BASED MEDICINE; HUMANS; URETHRAL DISEASES; URINARY BLADDER DISEASES; UROLOGIC DISEASES;

EID: 20744459321     PISSN: 17434270     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpuro0034     Document Type: Review

References (26)

1. Stewart WF et al. (2003) Prevalence and burden of overactive bladder in the Unites States. World J Urol 20: 327-336
2. Perfetto EM and Morris LS (1996) Agency for Health Care Policy and Research clinical practice guidelines. Ann Pharmacother 30: 117-121
3. Smith CP and Chancellor MB (2004) Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol 171: 2128-2137
4. Dykstra DD et al. (1988) Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 139: 919
5. Mall V et al. (2001) Treatment of neuropathic bladder using botulinum toxin A in a 1-year old child with myelomeningocele. Pediatr Nephrol 16: 1161-1162
6. Kuo HC (2003) Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction. J Urol 170: 1908-1912
7. Dykstra DD and Sidi A (1990) Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double blind study. Arch Phys Med Rehabil 71: 24-26
8. Petit H et al. (1998) Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease. Spinal Cord 36: 91-94
9. Phelan MW et al. (2001) Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol 165: 1107-1110
10. De Seze M et al. (2002) Botulinum A toxin and detrusor sphincter dyssynergia: A double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol 42: 56-62
11. Schurch B et al. (1996) Botulinum A toxin as a treatment of detrusor-sphincter dyssynergia; a prospective study in 24 spinal cord injury patients. J Urol 155: 1023-1029
12. McGuire EJ et al. (1981) The prognostic value of urodynamic testing in myelodysplastic patients. J Urol 126: 205-209
13. Kim YH et al. (1998) Bladder leak point pressure: The measure for sphincterotomy success in spinal cord injured patients with external detrusor-sphincter dyssynergia. J Urol 159: 493-496
14. Smith CP et al. (2002) Botulinum toxin urethral sphincter injection resolves urinary retention after pubovaginal sling operation. Int Urogynecol J Pelvic Floor Dysfunct 13: 185-186
15. Schurch B et al. (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results. J Urol 164: 692-697
16. Schulte-Baukloh H et al. (2003) Botulinum A-toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol 44: 139-143
17. Riccabona M et al. (2004) Botulinum-A toxin injection into the detrusor: A safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 171: 845-848
18. Reitz A and Schurch B (2004) Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity. J Urol 171: 804-805
19. Pistolesi D et al. (2004) Botulinum toxin type B for type A resistant bladder spasticity. J Urol 171: 802-803
20. Dykstra D et al. (2003) Treatment of overactive bladder with botulinum toxin type B: a pilot study. Int Urogynecol J Pelvic Floor Dysfunct 14: 424-426
21. Rapp DE et al. (2004) Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: An initial experience. Urology 63: 1071-1075
22. Reitz A et al. (2004) European experience of 200 cases treated with Botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45: 510-515
23. Giannantoni A et al. (2004) Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: A prospective randomized study. J Urol 172: 240-243
24. Smith CP et al. Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology, in press
25. Maria G, et al. (2003) Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: Results of a randomized, placebo-controlled study. Urology 62: 259-264
26. Gallien P et al. (1998) Treatment of detrusor sphincter dyssynergia by transperineal injection of botulinum toxin. Arch Phys Med Rehabil 79: 715-717